What You Need to Know Ahead of Thermo Fisher Scientific's Earnings Release

Clinical OMICsAsthma Drug Formoterol Shows Potential to Reverse MASH

Endpoints NewsRezdiffra is exceeding Wall Street's expectations as the MASH market takes shape

BioPharma DiveGSK cuts deal with Sino to broaden reach of hepatitis B drug

Endpoints NewsDaiichi eyes almost $15B in oncology sales by 2030 in ADC franchise push

Endpoints NewsNew home for Novo's Parkinson's cell therapy; GSK turns to China for hep B drug

Clinical OMICsBrain-Controlled Hearing Aid Singles Out Voices in a Crowd

BioWorldFirst cruise ship hantavirus genome points to zoonotic spillover

BioWorldBiggest gainers and losers for May 4-8, 2026

Endpoints NewsInhibrx says combo therapy shrank more tumors than Merck's Keytruda alone

FierceBiotechAmid M&A buzz, Inhibrx's OX40-Keytruda combo shows promise in early look at midphase data

FierceBiotechDaiichi Sankyo targets global top 5 oncology rank by 2035, $1.3B efficiency drive in new 5-year plan

PLoS BiologyThe problem with one-size-fits-all medicine: Biological sex and the aging immune system